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Abstract
Post-Traumatic Stress Disorder is a mental health condition brought on by witnessing or
experiencing distressing or terrifying events. Both MDMA and SSRIs like fluoxetine have
shown to aid in fear extinction and clinical recovery from PTSD. However, recent studies have
shown that MDMA used alongside therapy may have longer lasting effects on the anxiety
symptoms of PTSD and can result in quicker fear extinction responses compared to current
therapeutic methods using SSRIs. This review analyzes the knowledge and studies available
comparing the efficacy of MDMA-Assisted psychotherapy to traditional psychotherapy in
treating anxiety-related symptoms of PTSD in adults aged 18 to 40.
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PTSD is a mental health condition brought on by witnessing or experiencing
distressing or terrifying events
•
Symptoms of PTSD can be devastating and contribute to increased suicidality
•
Even with treatment, relapse is not uncommon. Of those who continued
traditional psychotherapy, 16.4% had relapsed after 24-28 weeks of treatment
MDMA-Assisted Psychotherapy
•
MDMA, or 3,4-methylenedioxymethamphetamine, is a psychoactive chemical
which stimulates the release of serotonin, oxytocin, prolactin, and cortisol
•
Up until it became a Schedule I drug in 1985, MDMA was used as in
therapeutic settings.
•
Researchers have further hypothesized that MDMA-Assisted Psychotherapy
has a stronger, longer lasting effect on reducing these symptoms of PTSD than
the traditional therapies used today

Methods
•
•

•

•

Performed November 2019
•
EBSCO, Google Scholar, and Google
Search Terms: “mdma-assisted psychotherapy” or “mdma assisted psychotherapy for ptsd
traditional therapy” or “mdma-assisted psychotherapy randomized controlled trial” or
“How does the efficacy of MDMA-Assisted Psychotherapy compare to the efficacy in
traditional psychotherapy in treating 18-40 year old adults diagnosed with Post-Traumatic
Stress Disorder (PTSD)”
Inclusion criteria
•
Peer reviewed and/or Scholarly
•
Published in 2013 or later
•
Discusses at least one of the following:
•
The effects of MDMA-assisted psychotherapy on PTSD
•
The effects of MDMA-assisted psychotherapy on anxiety
•
The pharmacodynamics of MDMA and how it can be used in
treatment for mental illness
•
Comparing MDMA-assisted psychotherapy to traditional
psychotherapy
Exclusion criteria
•
Articles which were not peer reviewed or scholarly
•
Articles which simply support or critique a previously chosen article without
providing new information regarding the PICO question
•
Articles which were written before 2013
•
Articles that did not fit any of the inclusion criteria listed above
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RCT of 6 participants comparing the efficacy of placebo-assisted psychotherapy to MDMA-Assisted psychotherapy in treating refractory PTSD
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Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., ... & Doblin, R. (2018). 3, 4-methylenedioxymethamphetamine
(MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind,
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1.
RCT of 26 participants followed by open label crossover after 2nd “experimental session” comparing the efficacy of “active control” assisted
psychotherapy to MDMA-Assisted psychotherapy in treating symptoms of PTSD

5/6 studies reported that MDMA-Assisted psychotherapy was more
beneficial in reducing symptoms of PTSD compared to traditional
psychotherapy
•

Strengths
•
•
•

•

All studies were based on RCTs
5/6 studies reported statistically significant results (P ≤
0.05)
3 studies reported a clinically and statistically significant
reduction in CAPS scores when compared to placeboassisted psychotherapy and prolonged exposure therapy,
while 2 studies reported a significant reduction in
SSPTSD scores and a significant reduction in Leibowitz
Social Anxiety Scale (LSAS) scores compared to placeboassisted psychotherapy

Weaknesses
•
Low number of participants
•
Many of these studies have participant populations that
are either over 75% white or fail to list the ethnicities of
the population tested à Not a diverse patient population
•
Lack of longitudinal studies
•
MDMA is a Schedule I substance in the United States

Table 1. Comparison of study designs. MDMA-AP vs Traditional therapy

Study

Population

1

Mean age = 31 +/- 8.8 years,
83.3% male, 16.7% female, 50% White

Placebo-assisted
psychotherapy

2

Mean age = 40.4 +/- 7.2 years, 17 females, 3
males, 100% White

Placebo-assisted
psychotherapy

Mean age = 41.4 +/- 11.2 years,
10 females, 2 males,
Ethnicity unlisted
MDMA-AP: Mean age = 40.9 +/- 9.2 years,
84.4% females, 15.6% males, ethnicity
unlisted

Placebo-assisted
psychotherapy

3
4

5

6

PE therapy: Mean age = 46.8 +/- 14.3 years,
12.9% females, 87.1% males, ethnicity
unlisted
Ages ranged from 29-49 years old, 100%
females, ethnicity unlisted

Mean age = 37 +/- 2 years old, 27% female,
73% male, 85% white

Therapy Compared

MDMA Dosing

Outcomes

75 mg during first
session, 100 mg during
second session
125 mg for each of the
two experimental
sessions
125 mg + 62.5 mg full
dose, 25 mg + 12.5 mg
“active placebo”
125 mg per session, 62.5
mg per session, 25 mg
per session, 12.5 mg per
session

LSAS

Placebo-assisted
psychotherapy

50 mg experimental
session, 75 mg per
experimental session

“Active control” (30
mg MDMA) assisted
psychotherapy

30mg for each of the
two sessions, 75 mg for
each of the two sessions,
125 mg for each of the
two sessions

STAI-S, SSSPTSD,
BDI,
HAM-D, MFS III,
MS,
SE/R,
HRS,
HAq
CAPS-IV Score,
BDI-II,
Mean PSQI,
PGTI score, GAF score, DES-II score, NEO-PIR

PE therapy

CAPS scores,
NEO-PI-R
CAPS scores, PDS scores,
CAPS scores,
PDS,
Cumulative effect size of primary outcomes,
Cumulative effect size of secondary outcomes,
cumulative dropout rates

Key: RCT = randomized controlled trial; LSAS = Leibowitz Social Anxiety Scale; CAPS = Clinician Administered PTSD scale; NEO-PI-R = The Revised NEO Personality Inventory; PE therapy = Prolonged Exposure Therapy; STAI-S = The State Trait Anxiety
Inventory, State Version; SSSPTSD = The Severity of Symptoms Scale for Post-traumatic Stress Disorder; BDI = The Beck Depression Inventory; HAM-D = The Hamilton Rating Scale; MFS III = The Modified Fear Scale; MS = The Maladjustment scale; SE/R =
The Rosenberg Self-esteem Scale; HRS = The Hallucinogen Rating Scale; HAq = The Penn Helping Alliance Questionnaire; CAPS-IV=Clinician-Administered PTSD Scale; BDI-II=Beck Depression Inventory-II; PSQI=Pittsburgh Sleep Quality Index; PTGI=PostTraumatic Growth Inventory; GAF=Global Assessment of Functioning; DES-II=Dissociative Experiences Scale II

Conclusion
Clinically speaking, these studies could support MDMA-Assisted
psychotherapy being a suitable option in reducing the anxiety symptoms
of PTSD which may be refractory to traditional psychotherapy. However
there are several gaps in the research and studies available
With such small patient populations, interpretation of these results simply
cannot be generalized to a larger patient population and studies involving
larger sample sizes are necessary to support the evidence of efficacy. Also,
the differences in population demographics in these studies can make it
difficult to support generalizing the evidence and recommending MDMAAssisted Psychotherapy when working with a diverse patient population.
There is also a lack of evidence in these studies supporting the long term
effects of MDMA-Assisted psychotherapy. Finally, MDMA also remains a
Schedule I substance in the United States, possessing and prescribing the
substance to patients can lead to criminal charges, making large scale,
longitudinal randomized controlled studies incredibly difficult to perform and
fund legally.
MDMA-Assisted psychotherapy has been showing promise as an
alternative breakthrough therapy for patients with refractory anxiety
symptoms of PTSD. However, an increase in larger longitudinal studies
with more diverse sample populations would be necessary before current
practices can be changed and the therapy can be recommended for
clinical use.

